In vivo IOL power determination possible

Article

Approximate in vivo intraocular lens (IOL) power can be determined using Scheimpflug imaging and could be applied in cases of unexplained postoperative refractive error.

Approximate in vivo intraocular lens (IOL) power can be determined using Scheimpflug imaging and could be applied in cases of unexplained postoperative refractive error, according to the results of a study published in the June issue of the Journal of Cataract and Refractive Surgery.

Stephen Turner and colleagues from the King's College Hospital Ophthalmology Department, London, UK assessed the feasibility of determining IOL power by measurement of the central optic thickness using clinically available Scheimpflug imaging. A total of 67 eyes were assessed one month after phacoemulsification with in-the-bag implantation of AcrySof MA60AC IOLs (Alcon). The correlation between IOL thickness measurement and IOL power was calculated and the repeatability of central optic thickness measurement was determined by 10 successive scans of four patients.

The coefficient of variability was 1.4% and the measured lens thickness was highly correlated with lens power (r2=0.94, p<0.001). Over the measured range, 95% confidence intervals varied between ±0.83 D and ±0.92 D.

The authors concluded that central IOL thickness measurements with the Scheimpflug camera are repeatable and closely correlate with the known IOL power, making in vivo IOL power determination a feasible option, especially in cases of unexplained postoperative refractive error.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.